Arcturus Total Current Liabilities from 2010 to 2024

ARCT Stock  USD 26.32  1.32  4.78%   
Arcturus Therapeutics Total Current Liabilities yearly trend continues to be comparatively stable with very little volatility. Total Current Liabilities is likely to outpace its year average in 2024. Total Current Liabilities is the total amount of liabilities that Arcturus Therapeutics Holdings is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. View All Fundamentals
 
Total Current Liabilities  
First Reported
2012-12-31
Previous Quarter
87.7 M
Current Value
82 M
Quarterly Volatility
39.8 M
 
Yuan Drop
 
Covid
Check Arcturus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcturus main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.1 M, Interest Expense of 530 K or Selling General Administrative of 55.5 M, as well as many exotic indicators such as Price To Sales Ratio of 5.06, Dividend Yield of 0.0 or PTB Ratio of 3.17. Arcturus financial statements analysis is a perfect complement when working with Arcturus Therapeutics Valuation or Volatility modules.
  
This module can also supplement Arcturus Therapeutics' financial leverage analysis and stock options assessment as well as various Arcturus Therapeutics Technical models . Check out the analysis of Arcturus Therapeutics Correlation against competitors.

Latest Arcturus Therapeutics' Total Current Liabilities Growth Pattern

Below is the plot of the Total Current Liabilities of Arcturus Therapeutics Holdings over the last few years. Total Current Liabilities is an item on Arcturus Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Arcturus Therapeutics Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Arcturus Therapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcturus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Current Liabilities10 Years Trend
Slightly volatile
   Total Current Liabilities   
       Timeline  

Arcturus Total Current Liabilities Regression Statistics

Arithmetic Mean33,397,963
Geometric Mean7,680,994
Coefficient Of Variation130.65
Mean Deviation36,950,618
Median11,040,000
Standard Deviation43,634,099
Sample Variance1903.9T
Range126.8M
R-Value0.84
Mean Square Error594.6T
R-Squared0.71
Significance0.00008
Slope8,221,461
Total Sum of Squares26655.1T

Arcturus Total Current Liabilities History

202486.1 M
202382 M
2022127 M
202199.5 M
202049.5 M
201921.3 M
201812.6 M

About Arcturus Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Arcturus Therapeutics income statement, its balance sheet, and the statement of cash flows. Arcturus Therapeutics investors use historical funamental indicators, such as Arcturus Therapeutics's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Arcturus Therapeutics investors may use each financial statement separately, they are all related. The changes in Arcturus Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Arcturus Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Arcturus Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Arcturus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Current Liabilities82 M86.1 M
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arcturus Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arcturus Therapeutics' short interest history, or implied volatility extrapolated from Arcturus Therapeutics options trading.

Pair Trading with Arcturus Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arcturus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arcturus Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Arcturus Stock

  0.64MRKR Marker TherapeuticsPairCorr
The ability to find closely correlated positions to Arcturus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arcturus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arcturus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arcturus Therapeutics Holdings to buy it.
The correlation of Arcturus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arcturus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arcturus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arcturus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Arcturus Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Arcturus Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Arcturus Therapeutics Holdings Stock. Highlighted below are key reports to facilitate an investment decision about Arcturus Therapeutics Holdings Stock:
Check out the analysis of Arcturus Therapeutics Correlation against competitors.
Note that the Arcturus Therapeutics information on this page should be used as a complementary analysis to other Arcturus Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for Arcturus Stock analysis

When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Is Arcturus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcturus Therapeutics. If investors know Arcturus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcturus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.12)
Revenue Per Share
6.264
Quarterly Revenue Growth
(0.81)
Return On Assets
(0.11)
Return On Equity
(0.11)
The market value of Arcturus Therapeutics is measured differently than its book value, which is the value of Arcturus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcturus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Arcturus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcturus Therapeutics' market value can be influenced by many factors that don't directly affect Arcturus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcturus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcturus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcturus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.